HSKA · Heska Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $62.38M | - | $61.49M | $64.68M | $64.80M | - | $60.24M | $64.93M | $30.65M | - |
| Cost of Revenue | $34.98M | - | $34.62M | $37.35M | $35.66M | - | $35.00M | $37.66M | $35.03M | - |
| Gross Profit | $27.40M | - | $26.88M | $27.33M | $29.14M | - | $25.24M | $27.27M | $25.47M | - |
| R&D | $3.09M | - | $2.38M | $2.33M | $12.46M | - | $1.96M | $1.95M | $1.19M | - |
| SG&A | $22.29M | - | $13.88M | $18.78M | $16.15M | - | $14.94M | $13.57M | $12.36M | - |
| Total Operating Expenses | $37.82M | - | $27.55M | $32.87M | $40.60M | - | $27.68M | $27.97M | $24.45M | - |
| D&A | $3.97M | - | - | - | $3.30M | - | - | - | $3.57M | - |
| Operating Income | ($10.42M) | - | ($671.0K) | ($5.54M) | ($11.45M) | - | ($2.43M) | ($694.0K) | $1.02M | - |
| Interest Expense | $939.0K | - | $1.17M | $931.0K | $925.0K | - | $918.0K | $922.0K | $920.0K | - |
| Income Tax | ($375.0K) | - | ($834.0K) | ($1.13M) | ($2.21M) | - | ($813.0K) | ($1.05M) | ($1.56M) | - |
| Net Income | ($9.99M) | - | ($436.0K) | ($5.25M) | ($9.99M) | - | ($1.90M) | ($567.0K) | $1.87M | - |
| EPS - Basic | ($0.97) | - | ($0.04) | ($0.51) | ($0.97) | - | ($0.19) | ($0.06) | $0.20 | - |
| EPS - Diluted | ($0.97) | - | ($0.04) | ($0.51) | ($0.97) | - | ($0.19) | ($0.06) | $0.19 | - |
Balance Sheet
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $125.21M | $156.62M | $161.07M | $171.93M | $172.74M | $223.57M | $222.90M | $245.15M | $238.46M | $86.33M |
| Accounts Receivable | $26.05M | $29.49M | $26.41M | $27.89M | $26.54M | $28.00M | $25.29M | $27.89M | $29.89M | $31.08M |
| Inventory | $64.18M | $60.05M | $57.48M | $55.80M | $55.22M | $49.36M | $45.04M | $41.20M | $39.36M | $40.04M |
| Accounts Payable | $12.25M | $16.40M | $14.75M | $12.05M | $12.38M | $15.37M | $12.06M | $14.58M | $14.96M | $15.12M |
| Current Assets | $238.62M | $265.03M | $262.81M | $272.87M | $272.75M | $319.56M | $311.62M | $330.84M | $322.76M | $171.28M |
| Total Assets | $592.72M | $585.82M | $570.07M | $586.79M | $601.67M | $604.07M | $597.19M | $579.37M | $569.57M | $399.84M |
| Current Liabilities | $42.30M | $39.58M | $36.59M | $39.46M | $40.53M | $43.93M | $37.93M | $41.48M | $37.79M | $42.12M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $175.04M | $163.61M | $162.17M | $169.50M | $173.08M | $168.22M | $162.35M | $145.60M | $144.30M | $112.79M |
| Stockholders' Equity | $417.67M | $422.21M | $407.90M | $417.29M | $428.60M | $435.85M | $434.84M | $433.77M | $425.27M | $287.05M |
| Retained Earnings | ($178.66M) | ($168.53M) | ($164.31M) | ($163.88M) | ($158.63M) | ($148.64M) | ($148.09M) | ($146.19M) | ($145.63M) | ($150.86M) |
Cash Flow
| Line item | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.16M) | - | - | - | ($17.66M) | - | - | - | $1.34M | - |
| Investing Cash Flow | ($22.56M) | - | - | - | ($29.84M) | - | - | - | ($13.13M) | - |
| Financing Cash Flow | ($128.0K) | - | - | - | ($3.26M) | - | - | - | $164.35M | - |
| CapEx | $1.89M | - | - | - | $334.0K | - | - | - | $262.0K | - |
| Free Cash Flow | ($11.05M) | - | - | - | ($18.00M) | - | - | - | $1.07M | - |
Ratios
| Metric | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 43.9% | - | 43.7% | 42.3% | 45.0% | - | 41.9% | 42.0% | 83.1% | - |
| Operating margin | -16.7% | - | -1.1% | -8.6% | -17.7% | - | -4.0% | -1.1% | 3.3% | - |
| EBITDA margin | -10.3% | - | - | - | -12.6% | - | - | - | 15.0% | - |
| Net margin | -16.0% | - | -0.7% | -8.1% | -15.4% | - | -3.2% | -0.9% | 6.1% | - |
| Free cash flow margin | -17.7% | - | - | - | -27.8% | - | - | - | 3.5% | - |
| FCF / Net income | 1.11 | - | - | - | 1.80 | - | - | - | 0.57 | - |
| R&D / Revenue | 5.0% | - | 3.9% | 3.6% | 19.2% | - | 3.2% | 3.0% | 3.9% | - |
| SG&A / Revenue | 35.7% | - | 22.6% | 29.0% | 24.9% | - | 24.8% | 20.9% | 40.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | -511.4% | - |
| Return on assets | -1.7% | - | -0.1% | -0.9% | -1.7% | - | -0.3% | -0.1% | 0.3% | - |
| Return on equity | -2.4% | - | -0.1% | -1.3% | -2.3% | - | -0.4% | -0.1% | 0.4% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.64 | 6.70 | 7.18 | 6.92 | 6.73 | 7.27 | 8.21 | 7.98 | 8.54 | 4.07 |
| Quick ratio | 4.12 | 5.18 | 5.61 | 5.50 | 5.37 | 6.15 | 7.03 | 6.98 | 7.50 | 3.12 |
| Cash ratio | 2.96 | 3.96 | 4.40 | 4.36 | 4.26 | 5.09 | 5.88 | 5.91 | 6.31 | 2.05 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -11.1x | - | -0.6x | -6.0x | -12.4x | - | -2.7x | -0.8x | 1.1x | - |
| Equity multiplier | 1.42 | 1.39 | 1.40 | 1.41 | 1.40 | 1.39 | 1.37 | 1.34 | 1.34 | 1.39 |
| Liabilities / Assets | 0.30 | 0.28 | 0.28 | 0.29 | 0.29 | 0.28 | 0.27 | 0.25 | 0.25 | 0.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.11 | 0.11 | 0.11 | - | 0.10 | 0.11 | 0.05 | - |
| Inventory turnover | 0.55 | - | 0.60 | 0.67 | 0.65 | - | 0.78 | 0.91 | 0.89 | - |
| Days sales outstanding | 152d | - | 157d | 157d | 149d | - | 153d | 157d | 356d | - |
| Days inventory outstanding | 670d | - | 606d | 545d | 565d | - | 470d | 399d | 410d | - |
| Days payable outstanding | 128d | - | 156d | 118d | 127d | - | 126d | 141d | 156d | - |
| Cash conversion cycle | 694d | - | 607d | 585d | 588d | - | 497d | 415d | 610d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -3.7% | - | 2.1% | -0.4% | 111.4% | - | 6.4% | 130.7% | 0.0% | - |
| Revenue CAGR (3y) | 26.7% | - | 25.3% | 32.0% | 30.0% | - | 24.8% | 29.8% | -2.2% | - |
| Revenue CAGR (5y) | 13.7% | - | 14.4% | 13.5% | 16.4% | - | 12.5% | 16.7% | 2.5% | - |
| Gross profit growth (YoY) | -6.0% | - | 6.5% | 0.2% | 14.4% | - | 7.9% | 52.7% | 89.4% | - |
| Operating income growth (YoY) | 9.0% | - | 72.4% | -698.6% | - | - | - | 84.4% | - | - |
| Net income growth (YoY) | 0.0% | - | 77.0% | -825.2% | - | - | 63.6% | 91.1% | - | - |
| EPS growth (YoY) | 0.0% | - | 78.9% | -750.0% | - | - | 66.7% | 91.7% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | -12.1% | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | 2.2% | - |
| FCF growth (YoY) | 38.6% | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -2.5% | -3.1% | -6.2% | -3.8% | 0.8% | 51.8% | 58.2% | 60.6% | 57.1% | 86.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Business segments
$253.74M totalNorth America Segment$158.90M · 62.6%
International Segment$94.84M · 37.4%
Product / service
$158.90M totalPoint Of Care Laboratory Revenue Consumables$72.00M · 45.3%
Point Of Care Laboratory Revenue Imaging$29.51M · 18.6%
Other Revenue Other Pharmaceuticals Vaccines And Diagnostic Tests$24.94M · 15.7%
OVP$17.61M · 11.1%
Point Of Care Laboratory Revenue Lab Instruments And Other$14.84M · 9.3%
Geographic
$253.74M totalUS$141.59M · 55.8%
DE$44.15M · 17.4%
FR$18.67M · 7.4%
CA$17.31M · 6.8%
ES$14.07M · 5.5%
IT$10.14M · 4.0%
Other International$3.92M · 1.5%
CH$3.88M · 1.5%
Peer comparison
Same SIC group: In Vitro & In Vivo Diagnostic Substances
Comparing HESKA CORP against the 5 most active filers in the same SIC group.